🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Deepa Rangachari

Harvard University

ORCID: 0000-0001-9710-6757

Also affiliated with Dana-Farber Cancer Institute

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile
0.757Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice

Cancers(2024)10.3390/cancers16061079
Top 27%
0.757DataRank
Top 27%17 citations

Andrew J. Piper‐Vallillo, Page Widick, Emmeline C. Academia, Meghan Shea, Deepa Rangachari +4 more

Papers

Driven by 15 papers — median percentile 73. Top paper: “Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?”.

Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2020-000697
N/A
2.6DataRank · unranked
50 citations

Andreas Varkaris, Hollis Viray, Paul A. VanderLaan, Deepa Rangachari, Daniel B. Costa +1 more

Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9507
N/A
1.5DataRank · unranked
39 citations

Daniel B. Costa, Cloud P. Paweletz, Mark M. Awad, Paul Marcoux, Deepa Rangachari +13 more

A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice

Cancers(2024)10.3390/cancers16061079
Top 27%
0.757DataRank
Top 27%17 citations

Andrew J. Piper‐Vallillo, Page Widick, Emmeline C. Academia, Meghan Shea, Deepa Rangachari +4 more

Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer

JTO Clinical and Research Reports(2020)10.1016/j.jtocrr.2020.100071
N/A
0.470DataRank · unranked
22 citations

Brian Halbert, Deepa Rangachari, Susumu Kobayashi, Daniel B. Costa, Andrew J. Piper‐Vallillo

Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?

Frontiers in Oncology(2020)10.3389/fonc.2020.01193
N/A
0.470DataRank · unranked
22 citations

Daniel B. Costa, Deepa Rangachari, Kartik Sehgal

EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors

Lung Cancer(2023)10.1016/j.lungcan.2023.107250
N/A
0.292DataRank · unranked
6 citations

Ikei S. Kobayashi, Daniel Sentana‐Lledo, Shriram K. Sundararaman, Meghan Lee, Deepa Rangachari +4 more

The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors

JTO Clinical and Research Reports(2023)10.1016/j.jtocrr.2023.100614
N/A
0DataRank · unranked
11 citations

William O. Shaffer, Hollis Viray, Deepa Rangachari, Paul A. VanderLaan, Susumu Kobayashi +2 more

ALK Deletion Exons 2 to 19: Case Report of a Rare ALK Inhibitor–Responsive Lung Cancer Driver Oncogene

JTO Clinical and Research Reports(2023)10.1016/j.jtocrr.2023.100489
N/A
0DataRank · unranked
0 citations

Emmeline C. Academia, Soravis A. Osataphan, Deepa Rangachari, Sheida Sharifi, Paul A. VanderLaan +2 more

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors

JTO Clinical and Research Reports(2020)10.1016/j.jtocrr.2020.100051
N/A
0DataRank · unranked
81 citations

Carol Gergis, Hollis Viray, Andreas Varkaris, Masanori Fujii, Deepa Rangachari +5 more

A Comprehensive Mutational and Histopathological Analysis of STK11-Mutant Non–Small Cell Lung Carcinomas

Modern Pathology(2025)10.1016/j.modpat.2025.100938
N/A
0DataRank · unranked
1 citations

Zoe Guan, Hyunwoo Kwon, Deepa Rangachari, Daniel B. Costa, Paul A. VanderLaan +1 more

Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer

Clinical Lung Cancer(2020)10.1016/j.cllc.2020.05.028
N/A
0DataRank · unranked
22 citations

Anushi Bulumulle, Heather Brody, Ritu R. Gill, Shravanti Macherla, Aleksandra Qilleri +10 more

Effect of performance status on survival with pembrolizumab monotherapy in advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9533
N/A
0DataRank · unranked
2 citations

Poorva Bindal, Anita G. Koshy, Ritu Gill, Danielle C. McDonald, Deepa Rangachari +2 more

Comparison of outcomes with pembrolizumab monotherapy (P) versus combination with chemotherapy (P+C) in advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e21579
N/A
0DataRank · unranked
0 citations

Ritu R. Gill, Poorva Bindal, Anita G. Koshy, Danielle C. McDonald, Deepa Rangachari +2 more

Association of Performance Status With Survival in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy

JAMA Network Open(2021)10.1001/jamanetworkopen.2020.37120
N/A
0DataRank · unranked
165 citations

Ritu R. Gill, Page Widick, Poorva Bindal, Danielle C. McDonald, Meghan Shea +3 more

EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates

Translational Lung Cancer Research(2023)10.21037/tlcr-23-98
N/A
0DataRank · unranked
33 citations

Emmeline C. Academia, Hollis Viray, Deepa Rangachari, Susumu Kobayashi, Paul A. VanderLaan +2 more